Literature DB >> 7890742

Primary structure of CD52.

A Treumann1, M R Lifely, P Schneider, M A Ferguson.   

Abstract

The CD52 antigen was extracted from human spleens with organic solvents and purified by immunoaffinity and reverse-phase chromatography. The latter step resolved two CD52 species, called CD52-I and CD52-II. Both species were found to contain similar N-linked oligosaccharides and glycosylphosphatidylinositol (GPI) anchor glycans. The N-linked oligosaccharides were characterized by methylation linkage analysis and, following exhaustive neuraminidase and endo-beta-galactosidase digestion, by the reagent array analysis method. The results showed that the single CD52 N-glycosylation site is occupied by large sialylated, polylactosamine-containing, core-fucosylated tetraantennary oligosaccharides. The locations of the phosphoryl substituents on the GPI anchor glycan were determined using a new and sensitive method based upon partial acid hydrolysis of the GPI glycan. The difference between CD52-I and CD52-II was in the phosphatidylinositol (PI) moieties of the GPI anchors. The phosphatidylinositol-specific phospholipase C-sensitive CD52-I contained exclusively distearoyl-PI, while the PI-phospholipase C-resistant CD52-II contained predominantly a palmitoylated stearoyl-arachidonoyl-PI, as judged by electrospray ionization mass spectrometry. Tandem mass spectrometric studies indicated that the palmitoyl residue of the CD52-II anchor is attached to the 2-position of the myo-inositol ring. Both the CD52-I and CD52-II PI structures are unusual for GPI anchors and the possible significance of this is discussed. The alkali-lability of the CD52 epitope recognized by the Campath-1H monoclonal antibody was studied. The data suggest that the alkali-labile hydroxyester-linked fatty acids of the GPI anchor are necessary for antibody binding.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7890742     DOI: 10.1074/jbc.270.11.6088

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  53 in total

Review 1.  Failure of hypomethylating agent-based therapy in myelodysplastic syndromes.

Authors:  Tapan M Kadia; Elias Jabbour; Hagop Kantarjian
Journal:  Semin Oncol       Date:  2011-10       Impact factor: 4.929

2.  Recognition of CD52 allelic gene products by CAMPATH-1H antibodies.

Authors:  C Hale; M Bartholomew; V Taylor; J Stables; P Topley; J Tite
Journal:  Immunology       Date:  1996-06       Impact factor: 7.397

3.  Antibody Distance from the Cell Membrane Regulates Antibody Effector Mechanisms.

Authors:  Kirstie L S Cleary; H T Claude Chan; Sonja James; Martin J Glennie; Mark S Cragg
Journal:  J Immunol       Date:  2017-04-12       Impact factor: 5.422

4.  Regulation unmasked by activation.

Authors:  Mike Clark; Anne Cooke
Journal:  Nat Immunol       Date:  2013-07       Impact factor: 25.606

5.  Molecular assembly of the aerolysin pore reveals a swirling membrane-insertion mechanism.

Authors:  Matteo T Degiacomi; Ioan Iacovache; Lucile Pernot; Mohamed Chami; Misha Kudryashev; Henning Stahlberg; F Gisou van der Goot; Matteo Dal Peraro
Journal:  Nat Chem Biol       Date:  2013-08-04       Impact factor: 15.040

6.  CD52 as both a marker and an effector molecule of T cells with regulatory action: Identification of novel regulatory T cells.

Authors:  Buka Samten
Journal:  Cell Mol Immunol       Date:  2013-09-16       Impact factor: 11.530

Review 7.  Recent progress in synthetic and biological studies of GPI anchors and GPI-anchored proteins.

Authors:  Shichong Yu; Zhongwu Guo; Charlie Johnson; Guofeng Gu; Qiuye Wu
Journal:  Curr Opin Chem Biol       Date:  2013-10-12       Impact factor: 8.822

8.  Variable CD52 expression in mature T cell and NK cell malignancies: implications for alemtuzumab therapy.

Authors:  Liuyan Jiang; Constance M Yuan; Julia Hubacheck; John E Janik; Wyndham Wilson; John C Morris; Gregory A Jasper; Maryalice Stetler-Stevenson
Journal:  Br J Haematol       Date:  2009-02-19       Impact factor: 6.998

Review 9.  Receptor-directed therapy of T-cell leukemias and lymphomas.

Authors:  John C Morris; Thomas A Waldmann; John E Janik
Journal:  J Immunotoxicol       Date:  2008-04       Impact factor: 3.000

Review 10.  Novel therapeutic strategies in adult acute lymphoblastic leukemia--a focus on emerging monoclonal antibodies.

Authors:  Naval Daver; Susan O'Brien
Journal:  Curr Hematol Malig Rep       Date:  2013-06       Impact factor: 3.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.